Valuation dashboard for Vericel Corporation (VCEL) with P/E 86.60, P/B 5.57, EV/EBITDA 52.6 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States.
Analysis Summary
Vericel Corporation reported revenue of $276.3M in the most recent fiscal year, growing at a 5-year CAGR of 17.3%. Net income reached $16.5M, with a 42.0% 5-year CAGR.
Trailing-twelve-month margins: gross margin 74.6%, operating margin 6.0%, net margin 7.9%.
At $40.51 (closing price, November 2, 2026), VCEL trades at a P/E of 86.60 and an ROE of 6.91%. Market capitalisation stands at $2.1B.
Balance sheet quality for VCEL: debt-to-equity ratio of 0.25, current ratio of 5.04 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 86.60 |
| Price / Book | 5.57 |
| EV / EBITDA | 52.6 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| VCEL | Vericel Corporation | $2.1B | 86.60 | 5.57 | 6.9% |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $55.0B | 41.27 | 6.54 | 16.9% |
| 0QNO.L | Lonza Group AG | CHF 43.8B | 5.43 | -1.3% |
Price
| Price | $40.51 (closing price, November 2, 2026) |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 6.91% |
| Return on Invested Capital | 3.79% |
| Return on Assets | 4.82% |
| Gross Margin | 74.56% |
| Operating Margin | 5.95% |
| Net Margin | 7.91% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of VCEL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks